Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany
Lang J, Kostev K, Reindl C, Müller T, Stritzelberger J, Gollwitzer S, Westermayer V, Trollmann R, Hamer H (2021)
Publication Type: Journal article
Publication year: 2021
Journal
Book Volume: 115
Article Number: 107705
DOI: 10.1016/j.yebeh.2020.107705
Abstract
Objective: Several publications on the exchangeability of antiepileptic drugs in clinical settings revealed an increased risk for seizure recurrence after changing the manufacturer of anti-seizure drugs (ASD) in adults, possibly due to a decline of adherence. It is unclear whether this holds true in children and adolescents. Methods: Patient data of children and adolescents (<18 years) were collected anonymously from 236 German pediatricians and pediatric neurologists between January 2011 and December 2018 using the IMS® Disease Analyzer database (IQVIA, Frankfurt, Germany). Patients with epilepsy were included if at least 2 prescriptions within 360 days and 1 within 180 days prior to the index date were available. The cohort was separated into a seizure group and seizure-free controls. Both groups were matched 1:1 according to age, gender, insurance status, and treating pediatrician. The risk for seizure recurrence after a manufacturer switch of the same ASD at the last prescription before the index date was analyzed using a multivariate regression model. Results: A total of 678 children and adolescents with epilepsy were included (each group: n = 339; age: 9.6 ± 4.4 years). Comparing both groups, the risk for seizures recurrence was not increased after a manufacturer switch had occurred. Albeit changes during the last prescription before the index date had occurred more often in the seizure-free group, neither change of branded and generic products nor substances reached significance. Only change of ASD strength showed a significantly reduced odds ratio for seizures (OR 0.40, 95% CI 0.24–0.65, p < 0.001). Significance: In contrast to the available evidence in adults, changing the manufacturer did not appear to increase the risk for seizure recurrence in previously seizure-free children and adolescents with epilepsy.
Authors with CRIS profile
Johannes Lang
Department of Neurology
Caroline Reindl
Department of Neurology
Tamara Welte
Department of Neurology
Jenny Stritzelberger
Department of Neurology
Regina Trollmann
Professur für Kinder- u. Jugendmedizin Schwerpunkt Neuropädiatrie
Hajo Hamer
Professur für Epileptologie
Involved external institutions
United States (USA) (US)How to cite
APA:
Lang, J., Kostev, K., Reindl, C., Müller, T., Stritzelberger, J., Gollwitzer, S.,... Hamer, H. (2021). Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany. Epilepsy and Behavior, 115. https://doi.org/10.1016/j.yebeh.2020.107705
MLA:
Lang, Johannes, et al. "Manufacturer switch of anti-seizure drugs may not increase the risk of seizure recurrence in Children: A nationwide study of prescription data in Germany." Epilepsy and Behavior 115 (2021).
BibTeX: Download